Falkson G, Falkson C I, Falkson C B
Department of Medical Oncology, University of Pretoria, Republic of South Africa.
Curr Opin Oncol. 1993 Jul;5(4):710-8. doi: 10.1097/00001622-199307000-00016.
During the past year, little of finite value has been published to change the approach to combined treatment modalities for the patient with gastrointestinal cancer. The value of adding other modalities to surgery to improve the cure rate has been marginal. Neoadjuvant and adjuvant treatment appear to be making inroads into the treatment of esophagus cancer, and newer development of less toxic treatment offers promise for the future. In stomach cancer, combined modality treatment is only of value for patients with locally advanced disease. In the United States, adjuvant chemotherapy is accepted as being of value for patients with colon cancer, and adjuvant treatment with both radiotherapy and chemotherapy is considered to be best for patients with surgically treatable rectum cancer. Primary liver cancer continues to offer a challenge for combined modality treatment, but a call for prospective, randomized control trials seems to be in order.
在过去的一年里，几乎没有什么具有有限价值的出版物能够改变胃肠道癌患者联合治疗模式的方法。在手术基础上增加其他治疗方式以提高治愈率的价值一直很有限。新辅助治疗和辅助治疗似乎正在进入食管癌的治疗领域，毒性较小的新疗法为未来带来了希望。在胃癌中，联合治疗模式仅对局部晚期疾病患者有价值。在美国，辅助化疗被认为对结肠癌患者有价值，而放疗和化疗联合辅助治疗被认为对可手术治疗的直肠癌患者是最佳选择。原发性肝癌仍然是联合治疗模式面临的挑战，但进行前瞻性随机对照试验的呼声似乎是合理的。
